An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 18 Years of Age With Solid Tumours Receiving Chemotherapy
Latest Information Update: 05 Jul 2022
At a glance
- Drugs GSK 137173A (Primary) ; Antineoplastics
- Indications Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms ZOSTER-028
- Sponsors GlaxoSmithKline
- 28 Jun 2022 According to a GlaxoSmithKline media release, based on data from six clinical trials (NCT01610414, NCT01798056, NCT01767467, NCT00920218, NCT01165203), the company has submitted regulatory application to the Japanese MHLW for Shingrix for the prevention of shingles in adults aged 18 years and older who are at increased risk. This includes individuals with immunodeficiency or immunosuppression caused by known disease or therapy.
- 01 Feb 2019 Results assessing immunogenicity and safety of recombinant zoster vaccine administered to patients with solid tumors (STs) before or at the start of a chemotherapy cycle, published in the Cancer.
- 08 Oct 2017 Results presented at the IDWeek 2017.